BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/20/2014 6:38:00 PM | Browse: 1170 | Download: 962
Publication Name World Journal of Gastroenterology
Manuscript ID 7330
Country United States
Received
2013-11-14 07:36
Peer-Review Started
2013-11-14 14:59
To Make the First Decision
2014-01-09 15:38
Return for Revision
2014-01-17 17:29
Revised
2014-01-25 04:29
Second Decision
2014-04-03 10:16
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-04-03 12:34
Articles in Press
2014-05-23 09:54
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-08-06 15:55
Publish the Manuscript Online
2014-08-20 18:38
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Topic Highlights
Article Title Recurrent hepatitis C after liver transplant
Manuscript Source Invited Manuscript
All Author List Andrew S deLemos, Paul A Schmeltzer and Mark W Russo
Funding Agency and Grant Number
Corresponding Author Mark W Russo, MD, MPH, Department of Medicine, Center for Liver Diseases and Transplantation, Carolinas Medical Center, 1000 Blythe Blvd, Charlotte, NC 28232-2861, United States. mark.russo@carolinashealthcare.org
Key Words Hepatitis C; Liver transplant; Donor risk factors; Immunosuppression; Protease inhibitors; Fibrosing cholestatic hepatitis C; Acute cellular rejection; Cytomegalovirus
Core Tip Recurrent hepatitis C impacts graft and patient survival following liver transplant. Preventing aggressive hepatitis C virus (HCV) recurrence by selecting appropriate donor allografts for HCV patients and careful management of immunosuppression in the post-transplant setting remain crucial. Direct acting antiviral therapy in patients awaiting transplant may prevent HCV re-infection post-transplant and has the potential to fundamentally change the natural history of hepatitis C in liver transplant recipients.
Publish Date 2014-08-20 18:38
Citation deLemos AS, Schmeltzer PA, Russo MW. Recurrent hepatitis C after liver transplant. World J Gastroenterol 2014; 20(31): 10668-10681
URL http://www.wjgnet.com/1007-9327/full/v20/i31/10668.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i31.10668
Full Article (PDF) WJG-20-10668.pdf
Full Article (Word) WJG-20-10668.doc
Manuscript File 7330-Review.doc
Answering Reviewers 7330-Answering reviewers.pdf
Copyright License Agreement 7330-Copyright assignment.pdf
Peer-review Report 7330-Peer reviews.pdf
Scientific Editor Work List 7330-Scientific editor work list.doc